The site you are about to enter is intended for US healthcare professionals.
Are you a US healthcare professional?
Confirm and enter Visit patient siteAttend a nearby educational event about AMVUTTRA® (vutrisiran)
Upcoming events
Patient Educational Event
Center Valley, Pennsylvania
February 10, 2026 |
6:00 PM-7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Sue, joined by Patient Ambassador, Scott, treated with AMVUTTRA.
Register
Patient Educational Event
Garden City, New York
February 19, 2026 |
6:00 PM-7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Christopher, joined by Patient Ambassador, Scott, treated with AMVUTTRA, and Dr. Naveen Bellam, a healthcare professional.
Register
Patient Educational Event
Franklin, Tennessee
February 21, 2026 |
11:30 AM-1:00 PM CT
Hear from an Alnylam Patient Education Liaison Nikki, joined by Ambassador, Ed, treated with AMVUTTRA and Penny, his spouse and caregiver, and Chris Bell, a healthcare professional.
Register
Patient Educational Event
Virtual Program
February 24, 2026 |
6:00 PM-7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Chris, joined by Patient Ambassador Al, treated with AMVUTTRA, and Deborah, their spouse and caregiver, and Dr. Naveen Bellam, a healthcare professional.
Register
Patient Educational Event
Glenview, Illinois
February 26, 2026 |
6:30 PM-8:00 PM CT
Hear from an Alnylam Patient Education Liaison, Angela, joined by Patient Ambassador, Art, treated with AMVUTTRA, and Ronald Zolty, a healthcare professional.
Register
Patient Educational Event
Stone Mountain, Georgia
March 05, 2026 |
6:00 PM-7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Valerie, joined by Patient Ambassador, Marty, treated with AMVUTTRA, and Naveen Bellam, a healthcare professional.
Register
Patient Educational Event
Wyomissing, Pennsylvania
March 17, 2026 |
6:00 PM-7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Sue, joined by Patient Ambassador, Scott, treated with AMVUTTRA.
Register
Patient Educational Event
King of Prussia, Pennsylvania
March 25, 2026 |
6:00 PM-7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Sue, joined by Patient Ambassador, Scott, treated with AMVUTTRA.
Register
Patient Educational Event
Virtual Program
March 26, 2026 |
7:00 PM-8:30 PM ET
Hear from an Alnylam Patient Education Liaison, Paul, joined by Patient Ambassador, Steve, treated with AMVUTTRA, and Dr. Brett Sperry, a healthcare professional.
Register
Patient Educational Event
Metairie, Louisiana
March 28, 2026 |
6:00 PM-7:30 PM CT
Hear from an Alnylam Patient Education Liaison, Diane, joined by Patient Ambassador, Al, treated with AMVUTTRA, and Deborah, their spouse and caregiver, and Chris Bell, a healthcare professional.
Register
Patient Educational Event
Cincinnati, Ohio
April 23, 2026 |
6:30 PM-8:00 PM ET
Hear from an Alnylam Patient Education Liaison, Shane, joined by Patient Ambassador, Kelly, treated with AMVUTTRA, and Olakunle Akinboboye, a healthcare professional.
Register
Patient Educational Event
Orange, Ohio
May 28, 2026 |
6:30 PM-8:00 PM ET
Hear from an Alnylam Patient Education Liaison, Shane, joined by Patient Ambassador, Marty, treated with AMVUTTRA, and Olakunle Akinboboye, a healthcare professional.
RegisterImportant Safety Information
What are the most important things I should know about AMVUTTRA® (vutrisiran)?
AMVUTTRA can cause low vitamin A levels
Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.
Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.
What are the common side effects of AMVUTTRA?
The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.
These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about AMVUTTRA, please see the full Prescribing Information.
Indications
What is AMVUTTRA?
AMVUTTRA is a prescription medicine that treats the:
- cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
- polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Important Safety Information and Indications
Important Safety Information
What are the most important things I should know about AMVUTTRA® (vutrisiran)?
AMVUTTRA can cause low vitamin A levels
Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.
Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.
What are the common side effects of AMVUTTRA?
The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.
These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about AMVUTTRA, please see the full Prescribing Information.
Indications
What is AMVUTTRA?
AMVUTTRA is a prescription medicine that treats the:
- cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
- polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.